Results 81 to 90 of about 14,439 (224)

Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa

open access: yesBiologics: Targets & Therapy, 2022
Radwa Ahmed Batran,1 Mai Elmoshneb,1 Ahmed Salah Hussein,1,2 Omar M Hussien,1 Fady Adel,1 Reham Elgarhy,1 Mosaad I Morsi1 1Medical Affairs Department, RAY Contract Research Organization, Giza, Egypt; 2Faculty of Medicine, Al-Azhar University, Cairo ...
Batran RA   +6 more
doaj  

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

open access: yesJAAD International, 2020
Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use.
Arnon D. Cohen, MD, MPH, PhD   +8 more
doaj   +1 more source

Recent Advances (2023–2025) of Capillary Electrophoresis‐Mass Spectrometry (CE‐MS) for Top‐Down Proteomics

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu   +5 more
wiley   +1 more source

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]

open access: yes, 2023
Stanley B Cohen,1,* Mariah Z Leach2,* 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; 2Mamas Facing Forward, Louisville, Colorado, USA*These authors contributed equally to this ...
Cohen SB, Leach MZ
core  

Evaluation of rheumatologists’ knowledge of biosimilars

open access: yesAdvances in Rheumatology
Introduction Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists’ knowledge and perceptions of biosimilars.
Thayane Furtado Rolim Lima   +3 more
doaj   +1 more source

Factors that Influence Healthcare Professionals' Intentions towards Biosimilars

open access: yesINNOVATIONS in Pharmacy
Background: Physicians often prescribe original biologic products to patients who have not used them before and are reluctant to switch to biosimilars.
Mohammed Alqahtani   +2 more
doaj   +1 more source

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai   +10 more
wiley   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Biologics & Biosimilars [PDF]

open access: yes, 2018
This presentation discusses the competition law issues raised by biosimilars. While many of the issues are similar to those raised by generics, the fact that, unlike generics, biosimilars are not exact copies of the original product means that the ...
Hull, David
core  

Anti-TNFα in inflammatory bowel disease: from originators to biosimilars

open access: yesFrontiers in Pharmacology
The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated inflammatory bowel disease (IBD) treatment and increased medical costs.
Zhen Zeng   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy